Answers are grounded in this paper and cite their sources.
Myeloablative autologous hematopoietic stem-cell transplantation achieved long-term benefits in patients with scleroderma, including improved event-free and overall survival, at a cost of increased expected toxicity. Rates of treatment-related death and post-transplantation use of DMARDs were lower than those in previous reports of nonmyeloablative transplantation. (Funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health; ClinicalTrials.gov number, NCT00114530 .).
No takes yet. Share an insight, caveat, or question.
Sullivan et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: